SE9302395D0 - New pharmaceutical formulation - Google Patents

New pharmaceutical formulation

Info

Publication number
SE9302395D0
SE9302395D0 SE19939302395A SE9302395A SE9302395D0 SE 9302395 D0 SE9302395 D0 SE 9302395D0 SE 19939302395 A SE19939302395 A SE 19939302395A SE 9302395 A SE9302395 A SE 9302395A SE 9302395 D0 SE9302395 D0 SE 9302395D0
Authority
SE
Sweden
Prior art keywords
pct
pharmaceutical formulation
new pharmaceutical
formulation
sec
Prior art date
Application number
SE19939302395A
Other languages
English (en)
Swedish (sv)
Inventor
Siv *Bengtsson Inga
Ingmar *Loevgren Kurt
Original Assignee
Ab Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9302395(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SE19939302395A priority Critical patent/SE9302395D0/xx
Application filed by Ab Astra filed Critical Ab Astra
Publication of SE9302395D0 publication Critical patent/SE9302395D0/xx
Priority to HR940386A priority patent/HRP940386B1/xx
Priority to IL11018994A priority patent/IL110189A0/xx
Priority to DZ940072A priority patent/DZ1794A1/fr
Priority to SA94150057A priority patent/SA94150057B1/ar
Priority to IS4187A priority patent/IS2034B/is
Priority to MYPI94001776A priority patent/MY128809A/en
Priority to ZA944934A priority patent/ZA944934B/xx
Priority to MA23568A priority patent/MA23258A1/fr
Priority to EG40894A priority patent/EG22373A/xx
Priority to HU9503874A priority patent/HU226779B1/hu
Priority to SK21-96A priority patent/SK281105B6/sk
Priority to YU43794A priority patent/YU49199B/sh
Priority to CA002166483A priority patent/CA2166483C/en
Priority to TNTNSN94078A priority patent/TNSN94078A1/fr
Priority to MX9405219A priority patent/MX9405219A/es
Priority to SG1996003536A priority patent/SG52365A1/en
Priority to EP94921155A priority patent/EP0706378B1/en
Priority to SI9430438T priority patent/SI0706378T1/xx
Priority to AU71982/94A priority patent/AU681686B2/en
Priority to NZ268694A priority patent/NZ268694A/en
Priority to RU96102154/14A priority patent/RU2138254C9/ru
Priority to JP50400695A priority patent/JP3665334B2/ja
Priority to KR1019960700052A priority patent/KR100350203B1/ko
Priority to CN94192734A priority patent/CN1126946A/zh
Priority to UA96010058A priority patent/UA43342C2/uk
Priority to ES94921155T priority patent/ES2191682T3/es
Priority to BR9406941A priority patent/BR9406941A/pt
Priority to AT94921155T priority patent/ATE231719T1/de
Priority to US08/313,036 priority patent/US5690960A/en
Priority to CZ199670A priority patent/CZ290323B6/cs
Priority to PL94312441A priority patent/PL175210B1/pl
Priority to DE69432076T priority patent/DE69432076T2/de
Priority to DK94921155T priority patent/DK0706378T3/da
Priority to PCT/SE1994/000681 priority patent/WO1995001783A1/en
Priority to EE9400419A priority patent/EE03148B1/xx
Priority to NO19960067A priority patent/NO315146B1/no
Priority to FI960102A priority patent/FI114008B/fi
Priority to HK98109229A priority patent/HK1008299A1/xx
Priority to LVP-04-07A priority patent/LV13140B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
SE19939302395A 1993-07-09 1993-07-09 New pharmaceutical formulation SE9302395D0 (sv)

Priority Applications (40)

Application Number Priority Date Filing Date Title
SE19939302395A SE9302395D0 (sv) 1993-07-09 1993-07-09 New pharmaceutical formulation
HR940386A HRP940386B1 (en) 1993-07-09 1994-07-01 New pharmaceutical formulation
IL11018994A IL110189A0 (en) 1993-07-09 1994-07-01 New pharmaceutical formulation
DZ940072A DZ1794A1 (fr) 1993-07-09 1994-07-03 Nouvelle formule pharmaceutique.
SA94150057A SA94150057B1 (ar) 1993-07-09 1994-07-04 خلطة صيدلانية pharmaceutical fomulaion من الاوميبرازول omeprazole
IS4187A IS2034B (is) 1993-07-09 1994-07-06 Ný lyfjablanda til inntöku um munn sem inniheldurnýtt magnesíumsalt ómeprasóls, aðferð við framleiðslu hennar og notkun
EG40894A EG22373A (en) 1993-07-09 1994-07-07 New pharmaceutical formulation
MA23568A MA23258A1 (fr) 1993-07-09 1994-07-07 Nouvelle formule contenant une nouvelle forme physique d'un sel magnesium d'omeprazole, son procede de fabrication et son utilisation.
MYPI94001776A MY128809A (en) 1993-07-09 1994-07-07 Pharmaceutical formulation of omeprazole
ZA944934A ZA944934B (en) 1993-07-09 1994-07-07 New pharmaceutical formulation
DK94921155T DK0706378T3 (da) 1993-07-09 1994-07-08 Ny farmaceutisk formulering.
PCT/SE1994/000681 WO1995001783A1 (en) 1993-07-09 1994-07-08 New pharmaceutical formulation
EP94921155A EP0706378B1 (en) 1993-07-09 1994-07-08 New pharmaceutical formulation
UA96010058A UA43342C2 (uk) 1993-07-09 1994-07-08 Фармацевтична композиція з ентеросолюбільним покриттям для орального введення, спосіб її одержання, спосіб інгібування секреції кислоти шлунком у ссавців і людини та спосіб лікування захворювань у ссавців і людини, що пов`язані з секрецією кислоти шлунком
YU43794A YU49199B (sh) 1993-07-09 1994-07-08 Nova farmaceutska formulacija magnezijum omeprazola i postupak za njeno dobijanje
CA002166483A CA2166483C (en) 1993-07-09 1994-07-08 New pharmaceutical formulation
TNTNSN94078A TNSN94078A1 (fr) 1993-07-09 1994-07-08 Nouvelle formule pharmaceutique
MX9405219A MX9405219A (es) 1993-07-09 1994-07-08 Nueva formulacion farmaceutica.
SG1996003536A SG52365A1 (en) 1993-07-09 1994-07-08 New pharmaceutical formulation
HU9503874A HU226779B1 (en) 1993-07-09 1994-07-08 Pharmaceutical formulation a novel physical form of the magnesium salt of omeprazole
SI9430438T SI0706378T1 (en) 1993-07-09 1994-07-08 New pharmaceutical formulation
AU71982/94A AU681686B2 (en) 1993-07-09 1994-07-08 New pharmaceutical formulation
NZ268694A NZ268694A (en) 1993-07-09 1994-07-08 Composition of magnesium omeprazole having a crystallinity greater than 70% having at least one subcoating and at least one enteric coating
RU96102154/14A RU2138254C9 (ru) 1993-07-09 1994-07-08 Фармацевтическая композиция с энтеросолюбильным покрытием, способ ее получения и способ лечения заболеваний
JP50400695A JP3665334B2 (ja) 1993-07-09 1994-07-08 新規な医薬処方物
KR1019960700052A KR100350203B1 (ko) 1993-07-09 1994-07-08 오메프라졸의신규제약제형
CN94192734A CN1126946A (zh) 1993-07-09 1994-07-08 新药物制剂
SK21-96A SK281105B6 (sk) 1993-07-09 1994-07-08 Stabilný orálny entericky potiahnutý prípravok, spôsob jeho výroby a jeho použitie
ES94921155T ES2191682T3 (es) 1993-07-09 1994-07-08 Nueva formulacion farmaceutica.
BR9406941A BR9406941A (pt) 1993-07-09 1994-07-08 Formulação oral com revestimento entèrico processo para a preparação da formulação processo para a inibição da secreção de acido gástrico em mamiferos e no homem e processo para o tratamento de doencas relacionados ao ácidos gástrico em mamiferos e no homem
AT94921155T ATE231719T1 (de) 1993-07-09 1994-07-08 Neue pharmazeutische formulierungen
US08/313,036 US5690960A (en) 1993-07-09 1994-07-08 Pharmaceutical formulation of omeprazole
CZ199670A CZ290323B6 (cs) 1993-07-09 1994-07-08 Stabilní orální entericky potaľený přípravek, způsob jeho výroby a pouľití
PL94312441A PL175210B1 (pl) 1993-07-09 1994-07-08 Doustny preparat farmaceutyczny i sposób wytwarzania doustnego preparatu farmaceutycznego
DE69432076T DE69432076T2 (de) 1993-07-09 1994-07-08 Neue pharmazeutische formulierungen
EE9400419A EE03148B1 (et) 1993-07-09 1994-11-17 Kristallilise magneesiumomeprasooli ravimvorm, selle valmistamise protsess ja kasutamine
NO19960067A NO315146B1 (no) 1993-07-09 1996-01-05 Oral enterisk belagt formulering, fremgangsmåte for dens fremstilling, og anvendelse derav
FI960102A FI114008B (fi) 1993-07-09 1996-01-09 Menetelmä oraalisen, suolistossa hajoavan päällystyksen omaavan valmisteen valmistamiseksi
HK98109229A HK1008299A1 (en) 1993-07-09 1998-07-17 New pharmaceutical formulation
LVP-04-07A LV13140B (en) 1993-07-09 2004-01-22 New pharmaceutical formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939302395A SE9302395D0 (sv) 1993-07-09 1993-07-09 New pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SE9302395D0 true SE9302395D0 (sv) 1993-07-09

Family

ID=20390587

Family Applications (1)

Application Number Title Priority Date Filing Date
SE19939302395A SE9302395D0 (sv) 1993-07-09 1993-07-09 New pharmaceutical formulation

Country Status (40)

Country Link
US (1) US5690960A (sh)
EP (1) EP0706378B1 (sh)
JP (1) JP3665334B2 (sh)
KR (1) KR100350203B1 (sh)
CN (1) CN1126946A (sh)
AT (1) ATE231719T1 (sh)
AU (1) AU681686B2 (sh)
BR (1) BR9406941A (sh)
CA (1) CA2166483C (sh)
CZ (1) CZ290323B6 (sh)
DE (1) DE69432076T2 (sh)
DK (1) DK0706378T3 (sh)
DZ (1) DZ1794A1 (sh)
EE (1) EE03148B1 (sh)
EG (1) EG22373A (sh)
ES (1) ES2191682T3 (sh)
FI (1) FI114008B (sh)
HK (1) HK1008299A1 (sh)
HR (1) HRP940386B1 (sh)
HU (1) HU226779B1 (sh)
IL (1) IL110189A0 (sh)
IS (1) IS2034B (sh)
LV (1) LV13140B (sh)
MA (1) MA23258A1 (sh)
MX (1) MX9405219A (sh)
MY (1) MY128809A (sh)
NO (1) NO315146B1 (sh)
NZ (1) NZ268694A (sh)
PL (1) PL175210B1 (sh)
RU (1) RU2138254C9 (sh)
SA (1) SA94150057B1 (sh)
SE (1) SE9302395D0 (sh)
SG (1) SG52365A1 (sh)
SI (1) SI0706378T1 (sh)
SK (1) SK281105B6 (sh)
TN (1) TNSN94078A1 (sh)
UA (1) UA43342C2 (sh)
WO (1) WO1995001783A1 (sh)
YU (1) YU49199B (sh)
ZA (1) ZA944934B (sh)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
EE03378B1 (et) * 1994-07-08 2001-04-16 Astra Aktiebolag Omeprasooli magneesiumisoola sisaldav peroraalne ravimvorm
US5817338A (en) * 1994-07-08 1998-10-06 Astra Aktiebolag Multiple unit tableted dosage form of omeprazole
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
AU719788B2 (en) * 1996-09-24 2000-05-18 Eli Lilly And Company Coated particle formulation
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
WO1998050019A1 (en) 1997-05-09 1998-11-12 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
AU1671799A (en) * 1997-11-28 1999-06-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
US20020039597A1 (en) * 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
JP4610086B2 (ja) 1998-11-18 2011-01-12 アストラゼネカ・アクチエボラーグ 改善された化学的方法および医薬処方物
US6365128B1 (en) * 1998-12-18 2002-04-02 Medical Defence Technologies, Llc Monitoring gastrointestinal function to guide care of high risk patients
AU4040800A (en) * 1999-03-29 2000-10-16 American Home Products Corporation Coating system
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
EP1222922B1 (en) 1999-10-20 2007-08-15 Eisai R&D Management Co., Ltd. Method for stabilizing benzimidazole compounds
EP1706397A4 (en) * 2000-05-15 2007-08-01 Ranbaxy Lab Ltd AMORPHOUS FORM OF OMEPRAZOLE SALTS
ES2191521B1 (es) * 2000-11-22 2005-02-16 Laboratorios Belmac, S.A. Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria.
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
WO2003032953A1 (fr) * 2001-10-17 2003-04-24 Takeda Chemical Industries, Ltd. Granules contenant un agent chimique instable en milieu acide, en concentration elevee
EP1469839A2 (en) * 2002-01-25 2004-10-27 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
WO2003075825A2 (en) * 2002-03-08 2003-09-18 Modi, Rajiv, Indravadan The method of treating tuberculosis
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
RU2332237C2 (ru) * 2002-08-02 2008-08-27 Рациофарм Гмбх Фармацевтический препарат, содержащий производное бензимидазола, смешанное с микрокристаллической целлюлозой, и способ его изготовления
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
AU2003900096A0 (en) * 2003-01-10 2003-02-20 Nature Vet Orally deliverable pharmaceutical composition protein pump inhibitors
ITMI20030616A1 (it) * 2003-03-28 2004-09-29 Acme Drugs S R L Metodo per la preparazione di farmaci, alimenti, integratori alimentari, gastroprotetti e/o a rilascio controllato, prodotti dietetici, premiscele per mangim,i additivi per l'alimentazione zootecnica contenenti principi attivi sensibili all'ambiente
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
WO2005020954A2 (en) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
US20050214388A1 (en) * 2004-02-18 2005-09-29 Gorham Thomas R Multivitamin formulations containing controlled-release magnesium
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2570916C (en) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
EP1830823A2 (en) 2004-12-23 2007-09-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US20080279951A1 (en) * 2005-02-02 2008-11-13 Rajesh Gandhi Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
WO2006090845A1 (ja) 2005-02-25 2006-08-31 Takeda Pharmaceutical Company Limited 顆粒の製造方法
AU2006299424A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
CA2654402A1 (en) * 2006-06-01 2007-12-06 Adel Penhasi Multiple unit pharmaceutical formulation
WO2008014175A2 (en) * 2006-07-28 2008-01-31 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
GB2444593B (en) 2006-10-05 2010-06-09 Santarus Inc Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
WO2009113090A2 (en) * 2008-01-17 2009-09-17 Alkem Laboratories Ltd. Process for preparing an oral formulation of an acid-sensitive benzimidazole drug
US8247440B2 (en) 2008-02-20 2012-08-21 Curators Of The University Of Missouri Composition comprising omeprazole, lansoprazole and at least one buffering agent
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US20110038933A1 (en) * 2008-05-06 2011-02-17 Dexcell Ltd. Stable benzimidazole formulation
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
EP2379063B2 (en) 2009-01-09 2021-02-24 Fwp Ip Aps Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
EP2445499A4 (en) 2009-06-25 2013-02-27 Astrazeneca Ab METHOD FOR TREATING A PATIENT WITH RISK OF DEVELOPING A NSAID-ASSOCIATED SPURGE
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
EP3711658A1 (en) 2011-06-14 2020-09-23 Gravitas Medical Inc. Apparatus for guiding medical care based on detected gastric function
CN104519888A (zh) 2011-12-28 2015-04-15 波曾公司 用于递送奥美拉唑和乙酰水杨酸的改良组合物和方法
CN103127026B (zh) * 2013-02-05 2017-02-15 悦康药业集团有限公司 一种奥美拉唑肠溶胶囊及其制备方法
CN103735526A (zh) * 2013-08-08 2014-04-23 上海海虹实业(集团)巢湖今辰药业有限公司 奥美拉唑镁肠溶片及其制作方法
CN103467453A (zh) * 2013-09-13 2013-12-25 上海海虹实业(集团)巢湖今辰药业有限公司 一种奥美拉唑镁原料药制备方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)
EP4098260A4 (en) 2020-01-27 2023-07-12 Towa Pharmaceutical Co., Ltd. ORAL PREPARATION OF EOMEPRAZOLE AND METHOD FOR PRODUCTION THEREOF
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
CN113350313B (zh) * 2021-06-23 2023-08-11 福建金山生物制药股份有限公司 一种艾司奥美拉唑镁延释制剂及其制备方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation

Also Published As

Publication number Publication date
AU7198294A (en) 1995-02-06
EP0706378A1 (en) 1996-04-17
EG22373A (en) 2002-12-31
DE69432076D1 (de) 2003-03-06
HRP940386A2 (en) 1997-02-28
HK1008299A1 (en) 1999-05-07
MY128809A (en) 2007-02-28
WO1995001783A1 (en) 1995-01-19
AU681686B2 (en) 1997-09-04
CA2166483A1 (en) 1995-01-19
DZ1794A1 (fr) 2002-02-17
US5690960A (en) 1997-11-25
KR100350203B1 (ko) 2002-12-28
ES2191682T3 (es) 2003-09-16
IL110189A0 (en) 1994-10-21
IS4187A (is) 1995-01-10
UA43342C2 (uk) 2001-12-17
ATE231719T1 (de) 2003-02-15
JPH08512316A (ja) 1996-12-24
NO960067D0 (no) 1996-01-05
ZA944934B (en) 1995-02-20
NO960067L (no) 1996-01-05
FI114008B (fi) 2004-07-30
CN1126946A (zh) 1996-07-17
TNSN94078A1 (fr) 1995-04-25
SG52365A1 (en) 1998-09-28
IS2034B (is) 2005-08-15
NZ268694A (en) 1997-05-26
PL175210B1 (pl) 1998-11-30
RU2138254C1 (ru) 1999-09-27
HRP940386B1 (en) 2003-10-31
HUT75306A (en) 1997-05-28
LV13140B (en) 2004-08-20
HU226779B1 (en) 2009-10-28
DE69432076T2 (de) 2003-10-16
HU9503874D0 (en) 1996-02-28
JP3665334B2 (ja) 2005-06-29
DK0706378T3 (da) 2003-05-05
CZ290323B6 (cs) 2002-07-17
MX9405219A (es) 1995-01-31
FI960102A (fi) 1996-01-09
PL312441A1 (en) 1996-04-29
CZ7096A3 (en) 1996-06-12
EP0706378B1 (en) 2003-01-29
BR9406941A (pt) 1996-09-10
RU2138254C9 (ru) 2009-09-27
CA2166483C (en) 1997-09-16
FI960102A0 (fi) 1996-01-09
SK2196A3 (en) 1997-04-09
MA23258A1 (fr) 1995-04-01
SI0706378T1 (en) 2003-06-30
YU43794A (sh) 1997-07-31
YU49199B (sh) 2004-09-03
SA94150057B1 (ar) 2006-10-03
SK281105B6 (sk) 2000-12-11
NO315146B1 (no) 2003-07-21
EE03148B1 (et) 1999-02-15

Similar Documents

Publication Publication Date Title
SE9302395D0 (sv) New pharmaceutical formulation
MY112915A (en) Multiple unit tableted dosage form 1
GEP20012375B (en) Isothiazolones, Pharmaceutical Composition on Their Basis and Method for Obtaining the Same
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
EP0793660A4 (en) 2-SUBSTITUTED 1,2,5-THIADIAZOLIDIN-3-ON-1,1-DIOXIDES, COMPOSITION AND THEIR USE
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
ATE107853T1 (de) Orales, melatonin enthaltendes arzneimittel.
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
DE69518229T2 (de) Hustenhemmende zusammensetzung die ein antitussivum und benzydamin enthält
SE9302218D0 (sv) New use
MX9704035A (es) 1,1-dioxidos de 2-(fosfiniloximetil)-1,2,5-tiadiazolidin-3-ona substituidos y composiciones y metodo de uso de los mismos.
JO1821B1 (en) New pharmaceutical product
MX9704036A (es) 1,1-dioxidos y composiciones de 2-(2,3,5,6-tetrafluoro-4-piridil)-1,2,5-thiadizaolidin-3-ona y metodo de uso.
ATE155136T1 (de) Neue bishispidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ATE221068T1 (de) Anellierte beta-carboline